DD209737A5 - Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut - Google Patents

Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut Download PDF

Info

Publication number: DD209737A5
Authority: DD; German Democratic Republic
Prior art keywords: molecular weight; daltons; solution; ultrafiltration; membranes
Prior art date: 1982-05-21

Application number

DD83251132A

Other languages

German (de)

English (en)

Inventor

Udo Wittenberger

Original Assignee

Solco Basel Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-05-21

Filing date

1983-05-20

Publication date

1984-05-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6164238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD209737(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1983-05-20 Application filed by Solco Basel Ag filed Critical Solco Basel Ag

1984-05-23 Publication of DD209737A5 publication Critical patent/DD209737A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 44
210000004369 blood Anatomy 0.000 title claims abstract description 30
239000008280 blood Substances 0.000 title claims abstract description 30
239000004480 active ingredient Substances 0.000 title description 11
FIVHOHCAXWQPGC-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)acetyl]oxyethyl-dimethylazanium;chloride Chemical compound Cl.CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 FIVHOHCAXWQPGC-UHFFFAOYSA-N 0.000 title 1
239000012528 membrane Substances 0.000 claims abstract description 42
238000000108 ultra-filtration Methods 0.000 claims abstract description 37
238000000909 electrodialysis Methods 0.000 claims abstract description 25
238000000926 separation method Methods 0.000 claims abstract description 25
239000012141 concentrate Substances 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 20
239000000126 substance Substances 0.000 claims abstract description 12
244000309466 calf Species 0.000 claims abstract description 11
230000036961 partial effect Effects 0.000 claims abstract description 9
230000035699 permeability Effects 0.000 claims abstract description 9
108090000623 proteins and genes Proteins 0.000 claims abstract description 9
102000004169 proteins and genes Human genes 0.000 claims abstract description 9
230000002829 reductive effect Effects 0.000 claims abstract description 5
239000000243 solution Substances 0.000 claims description 59
239000013543 active substance Substances 0.000 claims description 12
238000001914 filtration Methods 0.000 claims description 7
239000003011 anion exchange membrane Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000003010 cation ion exchange membrane Substances 0.000 claims description 3
150000001768 cations Chemical class 0.000 claims description 3
238000010790 dilution Methods 0.000 claims description 3
239000012895 dilution Substances 0.000 claims description 3
230000002949 hemolytic effect Effects 0.000 claims description 3
102000009123 Fibrin Human genes 0.000 claims description 2
108010073385 Fibrin Proteins 0.000 claims description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
229950003499 fibrin Drugs 0.000 claims description 2
239000000819 hypertonic solution Substances 0.000 claims description 2
229940021223 hypertonic solution Drugs 0.000 claims description 2
238000012423 maintenance Methods 0.000 claims description 2
238000003756 stirring Methods 0.000 claims description 2
230000000241 respiratory effect Effects 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 19
230000004071 biological effect Effects 0.000 description 14
239000003755 preservative agent Substances 0.000 description 14
239000000047 product Substances 0.000 description 14
230000000694 effects Effects 0.000 description 13
230000008569 process Effects 0.000 description 13
230000002335 preservative effect Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
239000003918 blood extract Substances 0.000 description 7
238000000502 dialysis Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
206010018910 Haemolysis Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000000052 comparative effect Effects 0.000 description 6
238000010612 desalination reaction Methods 0.000 description 6
239000003814 drug Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000008588 hemolysis Effects 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000006735 deficit Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000008223 sterile water Substances 0.000 description 4
239000002699 waste material Substances 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
229920002307 Dextran Polymers 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
230000001476 alcoholic effect Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
101100183412 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIN4 gene Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
-1 anionic ions Chemical class 0.000 description 2
101150022111 bel2 gene Proteins 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
238000004904 shortening Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
241000894006 Bacteria Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
241000160777 Hipparchia semele Species 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000004098 cellular respiration Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000000498 cooling water Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
208000006750 hematuria Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229910001410 inorganic ion Inorganic materials 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003014 ion exchange membrane Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000008590 mechanical hemolysis Effects 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000011368 organic material Substances 0.000 description 1
239000005416 organic matter Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
- B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/42—Electrodialysis; Electro-osmosis ; Electro-ultrafiltration; Membrane capacitive deionization
- B01D61/422—Electrodialysis
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/58—Multistep processes
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration

Landscapes

Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Water Supply & Treatment (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Virology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Developmental Biology & Embryology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Feed For Specific Animals (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Silver Salt Photography Or Processing Solution Therefor (AREA)
Steroid Compounds (AREA)
Fodder In General (AREA)

DD83251132A 1982-05-21 1983-05-20 Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut DD209737A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19823219248 DE3219248A1 (de)	1982-05-21	1982-05-21	Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut

Publications (1)

Publication Number	Publication Date
DD209737A5 true DD209737A5 (de)	1984-05-23

Family

ID=6164238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD83251132A DD209737A5 (de)	1982-05-21	1983-05-20	Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut

Country Status (13)

Country	Link
US (1)	US4599176A (fr)
EP (1)	EP0095170B2 (fr)
JP (1)	JPS58210021A (fr)
AT (2)	AT391807B (fr)
BE (1)	BE896807A (fr)
CH (1)	CH663539A5 (fr)
DD (1)	DD209737A5 (fr)
DE (2)	DE3219248A1 (fr)
FR (1)	FR2527079B1 (fr)
GB (1)	GB2130088B (fr)
HU (1)	HU190632B (fr)
PL (1)	PL139882B1 (fr)
YU (1)	YU43309B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT392003B (de) *	1988-01-13	1991-01-10	Broschek G Chem Prod Gebro	Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat
DE4429558A1 (de) *	1994-08-19	1996-02-22	Sanorell Pharma Gmbh & Co	Verfahren zur Herstellung von infektionsfreien pharmazeutischen Präparaten und/oder Nahrungsmitteln aus infektiösem Material
DE19518156C2 (de) *	1995-05-17	1997-05-07	Alfons Dr Pfister	Verwendung von deproteinisiertem Hämodialysat
DE19548630A1 (de) *	1995-12-12	1997-06-19	Schering Ag	Verfahren zur Reinigung von rekombinantem Human-Interleukin - 8
EA000633B1 (ru) *	1997-10-16	1999-12-29	Предприятие Диагностических И Лекарственных Препаратов "Диалек"	Способ получения биологически активного препарата из крови крупного рогатого скота и фармацевтическая композиция на его основе с радиопротекторной, антигипоксической, иммуномоделирующей, ранозаживляющей и противогерпетической активностью
RU2164142C1 (ru) *	2000-02-15	2001-03-20	Евгений Михайлович Шутаев	Способ получения биологически активного средства для нормализации физиологического состояния
EP1283047B1 (fr) *	2000-02-29	2007-01-17	OWEN Holding LTD	Procede de production d'une substance biologiquement active a partir du serum sanguin
CA2463655A1 (fr)	2001-10-15	2003-04-24	Chiron Corporation	Traitement de la pneumonie grave par administration d'un inhibiteur du mecanisme d'action du facteur tissulaire (tfpi)
BRPI0508992A (pt) *	2004-03-17	2007-09-04	Chiron Corp	tratamento de pneumonia severa pela administração de tfpi
DE102004047262A1 (de) *	2004-09-24	2006-04-06	Ipss International Pharmaceutical Strategies & Solutions	Pharmazeutisches Mittel umfassend Blutprodukte und deren Verwendung als Injektions- oder Infusionsmittel zur Prophylaxe und Behandlung von Defekten des Immunsystems beim Menschen
US20060067942A1 (en) *	2004-09-24	2006-03-30	Salama Zoser B	Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals
EP1640012A1 (fr) *	2004-09-24	2006-03-29	Salama, Zoser B. nat.rer.Dr.	Agents pharmaceutiques comprenant des constituants du sang 10 kDa et l'utilisation dans la prophylaxe et dans le traitement des troubles du système immunitaire
EP2886184A1 (fr)	2013-12-23	2015-06-24	Medizinische Universität Innsbruck	Élément électrochimique
CN109758912A (zh) *	2019-03-06	2019-05-17	康哲(湖南)制药有限公司	一种水解蛋白浓缩液专用超滤设备

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3973001A (en) *	1954-04-27	1976-08-03	Solco Basel Ag	Tissue cell stimulating blood extracts
GB824375A (en) *	1955-12-13	1959-11-25	Solco Basel Ag	Respiration-stimulant substances from blood
DE1076888B (de) *	1956-12-18	1960-03-03	Karl Heinz Jaeger Dr Med	Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke
DE1617355A1 (de) *	1967-08-19	1971-04-01	Boettger Kg Pharmazeutische Un	Verfahren zur Herstellung eines standardisierbaren Extraktes aus Blut und Knochenmark von Saeugetieren,vorzugsweise von Rindern
US3677923A (en) *	1968-04-15	1972-07-18	Milan Bier	Electroosmotic and electrodialysis concentration,purification,and desalting
GB1325673A (en) *	1969-07-16	1973-08-08	Atomic Energy Authority Uk	Reverse osmosis membrane assemblies
JPS5620287B2 (fr) *	1972-06-19	1981-05-13
DE2325196C2 (de) *	1973-05-18	1982-09-23	Böttger GmbH Pharmazeutische und Kosmetische Präparate, 1000 Berlin	Verfahren zur Herstellung eines eiweißfreien Extraktes aus hämolysiertem Blut
NL7413874A (nl) *	1973-10-26	1975-04-29	Nat Res Dev	Werkwijze voor het bereiden van stoffen tegen ontstekingen.
US3972791A (en) *	1974-05-06	1976-08-03	Harold Stern	Fractionation of proteins by electrical means
US3972614A (en) *	1974-07-10	1976-08-03	Radiometer A/S	Method and apparatus for measuring one or more constituents of a blood sample
JPS5124562A (en) *	1974-08-23	1976-02-27	Shinichi Tateno	Chushabarikanno seizohohoo
US3905886A (en) *	1974-09-13	1975-09-16	Aqua Chem Inc	Ultrafiltration and electrodialysis method and apparatus
DE2457463A1 (de) *	1974-12-05	1976-06-10	Hoechst Ag	Neue peptide mit blutdrucksenkender wirkung und verfahren zu ihrer herstellung
DE2512936C2 (de) *	1975-03-24	1982-01-14	Hellmut Dr. 8000 München Mittenzwei	Verfahren zur Abtrennung anorganischer Salze aus einem flüssigen peptid- und salzhaltigen Medium
US4043896A (en) *	1976-03-25	1977-08-23	Aqua-Chem, Inc.	Ultrafiltration and electrodialysis apparatus
JPS6043333B2 (ja) *	1976-08-20	1985-09-27	三共株式会社	抗炎症活性物質の製法
US4166948A (en) *	1977-12-01	1979-09-04	Dickey-John Corporation	Seed sensor
DE2946284A1 (de) *	1979-11-16	1981-05-21	Forschungsinstitut Berghof GmbH, 7400 Tübingen	Elektrodialyse-zellpaket
US4322275A (en) *	1980-01-10	1982-03-30	Ionics Incorporated	Fractionation of protein mixtures
US4276140A (en) *	1980-01-10	1981-06-30	Ionics Inc.	Electrodialysis apparatus and process for fractionating protein mixtures
HU183590B (en) *	1981-09-28	1984-05-28	Richter Gedeon Vegyeszet	Process for the isolation of an active suastance influencing specifically the nutrition centre with a regulative effect on the appetite from human and/or animal blood serum
JPS5936887A (ja) *	1982-08-24	1984-02-29	グローリー工業株式会社	硬貨識別装置
JPS6032640A (ja) *	1983-08-04	1985-02-19	田辺紙工機械製造株式会社	製箱機におけるフレ−ム移動方法

1982
- 1982-05-21 DE DE19823219248 patent/DE3219248A1/de not_active Withdrawn
1983
- 1983-05-02 CH CH2361/83A patent/CH663539A5/de not_active IP Right Cessation
- 1983-05-17 GB GB08313610A patent/GB2130088B/en not_active Expired
- 1983-05-18 HU HU831747A patent/HU190632B/hu not_active IP Right Cessation
- 1983-05-19 YU YU1123/83A patent/YU43309B/xx unknown
- 1983-05-19 AT AT0183983A patent/AT391807B/de not_active IP Right Cessation
- 1983-05-19 US US06/495,956 patent/US4599176A/en not_active Expired - Fee Related
- 1983-05-20 AT AT83105046T patent/ATE19249T1/de not_active IP Right Cessation
- 1983-05-20 BE BE0/210821A patent/BE896807A/fr not_active IP Right Cessation
- 1983-05-20 DE DE8383105046T patent/DE3363029D1/de not_active Expired
- 1983-05-20 DD DD83251132A patent/DD209737A5/de not_active IP Right Cessation
- 1983-05-20 FR FR8308418A patent/FR2527079B1/fr not_active Expired
- 1983-05-20 PL PL1983242091A patent/PL139882B1/pl unknown
- 1983-05-20 EP EP83105046A patent/EP0095170B2/fr not_active Expired - Lifetime
- 1983-05-20 JP JP58089915A patent/JPS58210021A/ja active Granted

Also Published As

Publication number	Publication date
JPS58210021A (ja)	1983-12-07
EP0095170A3 (en)	1984-06-06
DE3363029D1 (en)	1986-05-22
EP0095170B1 (fr)	1986-04-16
DE3219248A1 (de)	1983-11-24
CH663539A5 (de)	1987-12-31
GB2130088B (en)	1985-11-13
GB2130088A (en)	1984-05-31
EP0095170A2 (fr)	1983-11-30
EP0095170B2 (fr)	1992-02-05
YU43309B (en)	1989-06-30
YU112383A (en)	1987-02-28
ATA183983A (de)	1990-06-15
ATE19249T1 (de)	1986-05-15
BE896807A (fr)	1983-09-16
JPS647970B2 (fr)	1989-02-10
FR2527079A1 (fr)	1983-11-25
AT391807B (de)	1990-12-10
PL242091A1 (en)	1984-07-30
GB8313610D0 (en)	1983-06-22
PL139882B1 (en)	1987-03-31
US4599176A (en)	1986-07-08
FR2527079B1 (fr)	1986-04-18
HU190632B (en)	1986-09-29

Legal Events

Date	Code	Title	Description
1995-08-31	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69403077T2 (de)	1997-11-13	Verfahren und vorrichtung zur herstellung von liposomen
EP0095170B1 (fr)	1986-04-16	Procédé d'obtention de substances actives stimulant la respiration cellulaire, à partir du sang de veaux
DE69332959T2 (de)	2004-05-13	Lösungen für die Peritonealdialyse und deren Verwendung zum Verringern von Schädigungen an mesothelialen Zellen
DE2624373A1 (de)	1977-12-08	Verfahren und vorrichtung zur herstellung von steril filtrierten blutgerinnungsfaktoren
DE2948607A1 (de)	1981-06-11	Verfahren zur herstellung eines emulgators auf lecithinbasis
DE3021006A1 (de)	1981-01-08	Neues oberflaechenaktives material, verfahren zur herstellung desselben und dieses material enthaltendes pharmazeutisches mittel gegen hyalin-membran-erkrankung
DE69827787T2 (de)	2006-03-02	Verfahren zur entfernung von viren aus proteinlösungen mittels nanofiltration
EP0140134A2 (fr)	1985-05-08	Procédé de préparation d'un extrait biologiquement actif
EP0113447B1 (fr)	1988-02-10	Procédé de séparation fractionnée de mélanges de protéines au moyen de membranes
DE602005002461T2 (de)	2008-06-12	Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung, die dieses enthalten
EP0514421B1 (fr)	1995-08-16	Procede d'appauvrissement de virus contenus dans des solutions et de determination du taux d'appauvrissement de virus
DE1076888B (de)	1960-03-03	Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke
EP0493662B1 (fr)	1995-12-06	Utilisation de superoxyde dismutases pour la préparation de médicaments pour la prophylaxie et/ou le traitement de la défaillance d'organes de patients à risques ayant un traumatisme multiple causé par un accident
DE3019895C2 (fr)	1987-10-29
DE3101001A1 (de)	1981-12-03	Verfahren zur konzentration und reinigung des antihaemophilie-faktors oder faktor viii
DE2558537C2 (de)	1984-07-19	Verfahren zum Isolieren von Substanzen mit insulinähnlicher Wirksamkeit aus Blut oder Blutbestandteilen von Kälbern oder Schweinen
DE2428982A1 (de)	1975-01-16	Verfahren zur herstellung einer blutfraktion
DE4236346A1 (de)	1994-05-05	Wirkstoffgruppe, Verfahren zu ihrer Herstellung sowie ihre Verwendung
AT392003B (de)	1991-01-10	Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat
DE2855827C2 (de)	1986-06-12	Verfahren zur Gewinnung von Human-Chorion-Somatomammotropin
DE3115761A1 (de)	1982-08-12	Verfahren zum herstellen ungerinnbaren blutes unter anwendung proteolytischer enzyme und daraus gewonnenen proteinkonzentrates
KAWASHIMA	1923	Über die glykolytische Kraft des Blutes
AT137427B (de)	1934-05-11	Verfahren zur Gewinnung von an Vitaminen angereicherten Substanzen.
AT200257B (fr)	1958-10-25
DE2653534A1 (de)	1977-06-30	Antihaemophilen faktor enthaltendes, festes mittel und verfahren zu seiner herstellung